IAA
NRSN icon

Independent Advisor Alliance’s NeuroSense Therapeutics NRSN Stock Holding History

Independent Advisor Alliance’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72K Buy
100,000
+50,000
+100% +$39K ﹤0.01% 1020
2026
Q1 		$37.8K Buy
+50,000
New +$44.6K ﹤0.01% 1569

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Independent Advisor Alliance's NRSN Position: Q2 2026 in Review

Independent Advisor Alliance increased its NeuroSense Therapeutics (NRSN) stake by 100% in Q2 2026, buying an estimated $39K and bringing the position to 100,000 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #1020.

Independent Advisor Alliance first reported a position in NRSN in Q1 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • Independent Advisor Alliance held 100,000 shares of NeuroSense Therapeutics worth $72K as of Q2 2026.
  • Independent Advisor Alliance bought 50,000 NeuroSense Therapeutics shares in Q2 2026, an estimated $39K.
  • NeuroSense Therapeutics made up ﹤0.01% of Independent Advisor Alliance's portfolio in Q2 2026, its #1020 holding.
  • Independent Advisor Alliance first reported a position in NeuroSense Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Independent Advisor Alliance's 13F filing for Q2 2026, filed 12 Aug 2026.